ArticleCancer cell international2026
Sphingolipid metabolic subtyping defines SPHK1 as an oncogene and characterizes immunosuppressive TME features in gastric cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gastric cancer (GC) exhibits profound heterogeneity and poor clinical outcomes, underscoring the need for improved prognostic stratification and deeper insights into metabolism-immune interactions within the tumor microenvironment (TME). Although sphingolipid metabolic reprogramming is known to influence TME remodeling, systematic GC subtyping based on sphingolipid metabolism-related genes (SMGs) and the spatial regulatory roles of key metabolic enzymes remain insufficiently characterized. Using TCGA RNA sequencing data, we performed unsupervised clustering of SMGs and identified two metabolic subtypes. Cluster A was marked by upregulated sphingolipid metabolism, extensive extracellular matrix remodeling, and enrichment of immunosuppressive pathways, corresponding to significantly worse survival. Cluster B showed enrichment of energy metabolic programs and increased inflammatory immune infiltration, aligning with a more favorable prognosis. Spatial transcriptomic analysis revealed SPHK1 enrichment at the tumor invasive front, where high SPHK1 expression correlated with increased dendritic cell and neutrophil infiltration but not CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.